We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)’s share ...

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

Coherus BioSciences, Inc. ( NASDAQ: CHRS) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $50.7 million in its fourth quarter. The Redwood City, California-based company ...

The company said, “Coherus projects post-UDENYCA-close cash of approximately $250 million and cash runway projections exceeding two years, past ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences (NASDAQ:CHRS) on Tuesday, setting a price target of $30, which is approximately 95 ...

To get a sense of who is truly in control of Coherus BioSciences, Inc. (NASDAQ:CHRS), it is important to understand the ownership structure of the business. We can see that institutions own the ...

To get a sense of who is truly in control of Coherus BioSciences, Inc. (NASDAQ:CHRS), it is important to understand the ownership structure of the business. We can see that institutions own the lion's ...

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at ...